retatrutide mash just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Triple hormone receptor agonist retatrutide

This combination of effects leads to reduced calorie intake, which is the primary mechanism behind the significant weight loss observed in clinical trials

In contrast, there is no effect of sucralose on GLP-1 secretion in primary L-cell cultures in other reports [281,282], and infusion of artificial sweeteners does not affect glucose-stimulated GLP-1 secretion in healthy human volunteers [283,284]

I needed something warm and real, yet incredibly light

Restraint Supply shortages and compounding restrictions Australia is facing widespread shortages of GLP-1 receptor agonists such as semaglutide (Ozempic) and dulaglutide (Trulicity), since late 2022 and has been a major issue which is due to growing demand surpassing production, further affecting type 2 diabetes care, cardiovascular risk reduction and weight management in patients